Ibuprofen
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
Ibuprofen: From Pain and Inflammation to Acromesomelic Dysplasia, Hunter-Thompson Type
One-Sentence Summary
Ibuprofen is a widely marketed non-steroidal anti-inflammatory drug (NSAID), generally used for pain and inflammation. The TxGNN model predicts it may be effective for acromesomelic dysplasia, Hunter-Thompson type, a rare genetic skeletal disorder. Currently there are 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the supplied label data (ibuprofen is generally an NSAID for pain and inflammation) |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (ANDA/NDA licenses) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the supplied data. Ibuprofen is a non-selective COX inhibitor that reduces pain and inflammation, and its efficacy in those conditions is well established.
The predicted condition is a genetic skeletal dysplasia linked to the GDF5/CDMP1 pathway. A COX-related, disease-modifying mechanism is not evident, and no mechanistic link can be established from the supplied data. At most, ibuprofen might relieve pain symptomatically, but that is speculation rather than evidence of disease modification.
The high score (0.997, rank 7103) is a graph-based prediction only. The six other top predictions (brachyolmia-amelogenesis imperfecta syndrome, myosclerosis, brachyolmia, brachydactyly-syndactyly syndrome, pseudoachondroplasia, colobomatous microphthalmia-rhizomelic dysplasia syndrome) show the same pattern. Each has a score of about 0.996-0.997, no trials, no literature, and no established mechanism.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
Showing 5 of 20 authorizations.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA213794 | Ibuprofen (NuCare Pharmaceuticals, Inc.) | Tablet | Not listed |
| ANDA071935 | Ibuprofen (Amneal Pharmaceuticals of New York LLC) | Tablet | Not listed |
| ANDA078682 | Ibuprofen 200 (Walgreen Company) | Capsule, liquid filled | Not listed |
| ANDA076359 | Topcare Childrens Ibuprofen (Topco Associates LLC) | Tablet, chewable | Not listed |
| ANDA209179 | Childrens FLANAX Oral (Belmora LLC) | Suspension | Not listed |
Other dosage forms on the market include coated and film-coated tablets.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or literature (evidence level L5), and no plausible mechanism links COX inhibition to the underlying genetic cause of this condition. The high TxGNN score alone is not sufficient to justify further investment.
To proceed, the following is needed:
- Mechanism of action data (MOA) and a mechanistic rationale connecting ibuprofen to the GDF5/CDMP1 pathway
- Preclinical or observational evidence in this condition
- Package insert warnings and contraindications for safety screening
- Route and dosage form compatibility assessment for the new indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.